Glaxo Adds Alli Warning Label In Europe
This article was originally published in The Tan Sheet
Executive Summary
The European Union health authority recommended GlaxoSmithKline add a warning to alli nonprescription weight-loss drug, advising patients taking levothyroxine or antiepileptic drugs, or those with kidney disease, to consult a doctor before using